ProCE Banner Activity

Phase I NAVIGATOR Trial of Avapritinib in Patients With Metastatic GIST Harboring PDGFRA Exon 18 Mutations or as Fourth-line or Higher Therapy

Slideset Download
Conference Coverage
Avapritinib is active in patients with advanced GIST harboring PDGFRA Exon 18 mutations and in those who received ≥ 3 lines of prior therapies.

Released: June 05, 2019

Expiration: June 03, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro